Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27923357 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL3756497 | 0.82 | ALDH1A1 (0.60) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL24347012 | 0.82 | ALDH1A1 (0.60) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL9579513 | 0.82 | ALDH1A1 (0.59) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL19795773 | 0.81 | KMT2A (0.59) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL27552966 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL991531 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL3296385 | 0.80 | ALDH1A1 (0.57) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL522510 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL988839 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906193-B1 | MODIFIED HYALURONIC ACID DERIVATIVES AND USE THEREOF | SIGMA TAU IND FARMACEUTI (IT) | 2016-09-28 | — | — | EP | disclosed |
| US-20150252120-A1 | MODIFIED HYALURONIC ACID DERIVATIVES AND USE THEREOF | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-09-10 | — | — | US | disclosed |
| EP-2906193-A1 | MODIFIED HYALURONIC ACID DERIVATIVES AND USE THEREOF | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. (IT) | 2015-08-19 | — | — | EP | disclosed |
| US-20140322149-A1 | COMPOUND USEFUL FOR TREATING CELLULITE | SIGMA TAU IND FARMACEUTI (IT) | 2014-10-30 | — | — | US | disclosed |
| US-20110217252-A1 | COMPOUND USEFUL FOR TREATING CELLULITE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2011-09-08 | — | — | US | disclosed |
| EP-2344153-A1 | COMPOUND USEFUL FOR TREATING CELLULITE | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2011-07-20 | — | — | EP | disclosed |
| US-7854939-B2 | Gel useful for the delivery of cosmetic active ingredients | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| WO-2010054978-A1 | COMPOUND USEFUL FOR TREATING CELLULITE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-20 | — | — | WO | disclosed |
| EP-2152225-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2010-02-17 | — | — | EP | disclosed |
| US-20090312421-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2009-12-17 | — | — | US | disclosed |
| WO-2008138393-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-20 | — | — | WO | disclosed |
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-11-13 | — | — | US | disclosed |
| EP-1214048-B1 | USE OF CONJUGATED LINOLEIC ACID (CLA) FOR THE TOPICAL TREATMENT OF CELLULITE | PENTAPHARM LTD (CH) | 2006-03-29 | — | — | EP | disclosed |
| US-6953583-B1 | Use of conjugated linoleic acid (CLA) for the topical treatment of cellulite | PENTAPHARM AG (CH) | 2005-10-11 | — | — | US | disclosed |
| EP-1214048-A1 | USE OF CONJUGATED LINOLEIC ACID (CLA) FOR THE TOPICAL TREATMENT OF CELLULITE | PENTAPHARM Ltd. (CH) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001017498-A1 | USE OF CONJUGATED LINOLEIC ACID (CLA) FOR THE TOPICAL TREATMENT OF CELLULITE | PENTAPHARM LTD. (CH) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252120-A1 | MODIFIED HYALURONIC ACID DERIVATIVES AND USE THEREOF | CD44, MMP1, GLA | ALDH1A1 37/4885KMT2A 3302/4885TDP1 1905/4885 |
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SLC25A20, CRAT, CUTA | ALDH1A1 2427/4885KMT2A 3957/4885TDP1 2299/4885 |
| US-20090312421-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SLC25A20, CRAT, UGCG | ALDH1A1 1957/4885KMT2A 3926/4885TDP1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.